

Deepali Kumar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8119861/publications.pdf>

Version: 2024-02-01

110
papers

7,512
citations

71102

41
h-index

56724

83
g-index

111
all docs

111
docs citations

111
times ranked

9157
citing authors

#	ARTICLE	IF	CITATIONS
1	The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. <i>Transplantation</i> , 2018, 102, 900-931.	1.0	784
2	Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. <i>Transplantation</i> , 2013, 96, 333-360.	1.0	651
3	Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 1244-1246.	27.0	456
4	Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 521-526.	9.1	329
5	Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. <i>Clinical Transplantation</i> , 2019, 33, e13563.	1.6	307
6	Clinical Impact of Community-Acquired Respiratory Viruses on Bronchiolitis Obliterans After Lung Transplant. <i>American Journal of Transplantation</i> , 2005, 5, 2031-2036.	4.7	249
7	Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 56, 817-824.	5.8	243
8	COVID-19: A global transplant perspective on successfully navigating a pandemic. <i>American Journal of Transplantation</i> , 2020, 20, 1773-1779.	4.7	189
9	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 498-510.	10.7	180
10	Cytomegalovirus (CMV) Virus Load Kinetics to Predict Recurrent Disease in Solid-Organ Transplant Patients with CMV Disease. <i>Journal of Infectious Diseases</i> , 2002, 186, 829-833.	4.0	169
11	A Prospective Molecular Surveillance Study Evaluating the Clinical Impact of Community-Acquired Respiratory Viruses in Lung Transplant Recipients. <i>Transplantation</i> , 2010, 89, 1028-1033.	1.0	150
12	Coronavirus disease 2019: Implications of emerging infections for transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1768-1772.	4.7	149
13	A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 67, 1322-1329.	5.8	145
14	A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1698-1704.	5.8	141
15	Severe Acute Respiratory Syndrome (SARS) in a Liver Transplant Recipient and Guidelines for Donor SARS Screening. <i>American Journal of Transplantation</i> , 2003, 3, 977-981.	4.7	131
16	State-of-the-Art Monitoring of Cytomegalovirus-Specific Cell-Mediated Immunity After Organ Transplant: A Primer for the Clinician. <i>Clinical Infectious Diseases</i> , 2012, 55, 1678-1689.	5.8	128
17	Randomized, Double-Blind, Controlled Trial of Pneumococcal Vaccination in Renal Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2003, 187, 1639-1645.	4.0	121
18	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3980-3989.	4.7	120

#	ARTICLE	IF	CITATIONS
19	Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia. <i>Transplantation</i> , 2012, 93, 195-200.	1.0	119
20	A Surveillance Study of Adenovirus Infection in Adult Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 2555-2559.	4.7	118
21	IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza. <i>PLoS Pathogens</i> , 2014, 10, e1004556.	4.7	108
22	Clinical immune monitoring strategies for predicting infection risk in solid organ transplantation. <i>Clinical and Translational Immunology</i> , 2014, 3, e12.	3.8	107
23	Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: a Phase III, Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2020, 70, 181-190.	5.8	104
24	The Clinical Utility of Whole Blood Versus Plasma Cytomegalovirus Viral Load Assays for Monitoring Therapeutic Response. <i>Transplantation</i> , 2011, 91, 231-236.	1.0	87
25	Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 192-201.	10.7	87
26	A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2505-2516.	4.7	84
27	Incidence and Clinical Characteristics of Herpes Zoster After Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 11-16.	0.6	79
28	Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. <i>Nature Immunology</i> , 2022, 23, 380-385.	14.5	78
29	Seasonal influenza vaccine in immunocompromised persons. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1311-1322.	3.3	76
30	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 649-657.	8.1	76
31	A Randomized, Double-Blind Trial of Pneumococcal Vaccination in Adult Allogeneic Stem Cell Transplant Donors and Recipients. <i>Clinical Infectious Diseases</i> , 2007, 45, 1576-1582.	5.8	74
32	Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus. <i>Journal of Infectious Diseases</i> , 2014, 210, 717-727.	4.0	68
33	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Prime-Boost Strategy for Pneumococcal Vaccination in Adult Liver Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2008, 47, 885-892.	5.8	67
34	Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 617-631.	5.8	67
35	An Assessment of Donor-Recipient Transmission Patterns of Human Cytomegalovirus by Analysis of Viral Genomic Variants. <i>Journal of Infectious Diseases</i> , 2009, 199, 1621-1628.	4.0	64
36	Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients. <i>Transplantation</i> , 2016, 100, 662-669.	1.0	62

#	ARTICLE	IF	CITATIONS
37	Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. <i>American Journal of Transplantation</i> , 2022, 22, 2089-2093.	4.7	61
38	Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018. <i>Pediatric Transplantation</i> , 2019, 23, e13571.	1.0	59
39	Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study. <i>CMAJ Open</i> , 2021, 9, E181-E188.	2.4	49
40	A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors. <i>American Journal of Transplantation</i> , 2021, 21, 2623-2624.	4.7	49
41	Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 679-684.	0.6	46
42	Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1392-1397.	5.8	46
43	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine. <i>Annals of Internal Medicine</i> , 2022, 175, 226-233.	3.9	46
44	Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave. <i>Clinical Infectious Diseases</i> , 2022, 75, 2193-2200.	5.8	40
45	Emerging viral infections in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 337-341.	3.1	39
46	Comparison of the Effect of Standard and Novel Immunosuppressive Drugs on CMV-Specific T-Cell Cytokine Profiling. <i>Transplantation</i> , 2013, 95, 448-455.	1.0	38
47	Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2365-2374.	5.8	36
48	Respiratory Viral Infections in Transplant and Oncology Patients. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 395-412.	5.1	32
49	Survey of current transplant center practices regarding COVID-19 vaccine mandates in the United States. <i>American Journal of Transplantation</i> , 2022, 22, 1705-1713.	4.7	32
50	An Analysis of Regulatory T-Cell and Th-17 Cell Dynamics during Cytomegalovirus Replication in Solid Organ Transplant Recipients. <i>PLoS ONE</i> , 2012, 7, e43937.	2.5	30
51	Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 718-730.	9.1	30
52	A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies. <i>JCI Insight</i> , 2018, 3, .	5.0	29
53	Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination. <i>Journal of Infectious Diseases</i> , 2015, 212, 137-146.	4.0	28
54	Cytomegalovirus infection and graft rejection as risk factors for pneumocystis pneumonia in solid organ transplant recipients: A systematic review and meta-analysis. <i>Clinical Transplantation</i> , 2018, 32, e13339.	1.6	27

#	ARTICLE	IF	CITATIONS
55	T-cell responses following Natural Influenza Infection or Vaccination in Solid Organ Transplant Recipients. <i>Scientific Reports</i> , 2020, 10, 10104.	3.3	27
56	Outbreak of pseudomonas aeruginosa by multiple organ transplantation from a common donor1. <i>Transplantation</i> , 2003, 75, 1053-1055.	1.0	26
57	Influenza vaccine strategies for solid organ transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 309-315.	3.1	26
58	Marijuana use in transplantation: A call for clarity. <i>Clinical Transplantation</i> , 2019, 33, e13456.	1.6	26
59	Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial. <i>Clinical Infectious Diseases</i> , 2016, 62, 1154-1160.	5.8	24
60	Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2316-2323.	1.0	24
61	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019, 46, 751-754.	2.0	22
62	Impaired T Cell Responsiveness to Interleukin-6 in Hematological Patients with Invasive Aspergillosis. <i>PLoS ONE</i> , 2015, 10, e0123171.	2.5	21
63	Underimmunization of the solid organ transplant population: An urgent problem with potential digital health solutions. <i>American Journal of Transplantation</i> , 2020, 20, 34-39.	4.7	20
64	Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2495-2504.	4.7	19
65	Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2175-2183.	1.0	19
66	Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 287-297.	0.6	19
67	Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 57-65.	1.3	18
68	Immunizations in solid organ and hematopoietic stem cell transplant patients: A comprehensive review. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2852-2863.	3.3	17
69	Baseline serum interleukin-6 to interleukin-2 ratio is associated with the response to seasonal trivalent influenza vaccine in solid organ transplant recipients. <i>Vaccine</i> , 2015, 33, 7176-7182.	3.8	16
70	Foreword: 4th edition of the American Society of Transplantation Infectious Diseases Guidelines. <i>Clinical Transplantation</i> , 2019, 33, e13642.	1.6	16
71	Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation. <i>EBioMedicine</i> , 2020, 60, 102994.	6.1	16
72	Long Term Immune Responses to Pandemic Influenza A/H1N1 Infection in Solid Organ Transplant Recipients. <i>PLoS ONE</i> , 2011, 6, e28627.	2.5	16

#	ARTICLE	IF	CITATIONS
73	Severe Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 1849-1860.	4.0	16
74	A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 3150-3169.	4.7	16
75	Outcomes of SARS-CoV-2 Infection in Unvaccinated Compared With Vaccinated Solid Organ Transplant Recipients: A Propensity Matched Cohort Study. <i>Transplantation</i> , 2022, 106, 1622-1628.	1.0	15
76	Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0171621.	3.9	15
77	Attitudes of Liver Transplant Candidates Toward Organs From Increased-Risk Donors. <i>Liver Transplantation</i> , 2019, 25, 881-888.	2.4	14
78	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. <i>PLoS Pathogens</i> , 2017, 13, e1006299.	4.7	12
79	Tacrolimus Impairs Kupffer Cell Capacity to Control Bacteremia: Why Transplant Recipients Are Susceptible to Infection. <i>Hepatology</i> , 2021, 73, 1967-1984.	7.3	11
80	Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2246-2253.	4.7	11
81	Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients. <i>Clinical Transplantation</i> , 2017, 31, e13000.	1.6	10
82	Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2020, 221, 53-62.	4.0	10
83	Clinical predictors of progression and clearance of low-level CMV DNAemia in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13207.	1.7	9
84	Case 29-2020: A 66-Year-Old Man with Fever and Shortness of Breath after Liver Transplantation. <i>New England Journal of Medicine</i> , 2020, 383, 1168-1180.	27.0	9
85	Organ utilization from increased infectious risk donors: An observational study. <i>Transplant Infectious Disease</i> , 2017, 19, e12785.	1.7	8
86	Vaccination for the post-kidney transplant population. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 581-586.	2.0	8
87	A Survey of Increased Infectious Risk Donor Utilization in Canadian Transplant Programs. <i>Transplantation</i> , 2016, 100, 461-464.	1.0	7
88	Reply to Hamilton. <i>Clinical Infectious Diseases</i> , 2018, 67, 1956-1956.	5.8	7
89	Natural influenza infection produces a greater diversity of humoral responses than vaccination in immunosuppressed transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2709-2718.	4.7	7
90	Influenza Virus Infection and Transplantation. <i>Transplantation</i> , 2021, 105, 968-978.	1.0	7

#	ARTICLE	IF	CITATIONS
91	Chronic <i>Candida dubliniensis</i> meningitis in a lung transplant recipient. <i>Medical Mycology Case Reports</i> , 2019, 24, 41-43.	1.3	6
92	Humoral response to natural influenza infection in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 2318-2328.	4.7	6
93	Potential role of <i>CCR6</i> chemokine receptor 6 in prediction of late-onset cytomegalovirus infection following solid organ transplant. <i>Clinical Transplantation</i> , 2015, 29, 492-498.	1.6	5
94	CMV immune monitoring—Where do we go from here?. <i>American Journal of Transplantation</i> , 2020, 20, 1961-1962.	4.7	5
95	Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study. <i>Transplant Infectious Disease</i> , 2021, 23, e13743.	1.7	5
96	Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management. <i>Drugs and Aging</i> , 2017, 34, 743-754.	2.7	4
97	Echinocandin use in lung transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13437.	1.6	4
98	Conservative Pancreas Graft Preservation at the Extreme. <i>Transplantation Direct</i> , 2016, 2, e50.	1.6	3
99	Cytokine profile in lung transplant recipients with <i>Aspergillus</i> spp colonization. <i>Transplant Infectious Disease</i> , 2019, 21, e13060.	1.7	3
100	Long-lasting cluster of nosocomial pneumonia with a single <i>Pneumocystis jirovecii</i> genotype involving different organ allograft recipients. <i>Clinical Transplantation</i> , 2020, 34, e14108.	1.6	3
101	Innate and Adaptive Immune Correlates of Chronic and Self-limiting EBV DNAemia in Solid-organ Transplant Recipients. <i>Transplantation</i> , 2020, 104, 2373-2382.	1.0	3
102	The economic impact of increased length of stay associated with surgical site infections in liver transplantation on Canadian healthcare costs. <i>Clinical Transplantation</i> , 2021, 35, e14155.	1.6	3
103	Respiratory Viruses in Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 2146.	3.3	3
104	Characterization and predictive functional profiles on metagenomic 16S rRNA data of liver transplant recipients: A longitudinal study. <i>Clinical Transplantation</i> , 2021, 36, e14534.	1.6	3
105	A Pilot Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	2
106	Late Posttransplant Period: Posttransplant Vaccination, Travel Advice, Foodborne Infections. , 2019, , 51-62.		1
107	Reply to Dunbar, Schauvlieghe and Rijnders. <i>Clinical Infectious Diseases</i> , 2019, 69, 2037-2038.	5.8	0
108	Vaccination Strategies in Solid Organ and Stem Cell Transplant. , 2021, , 253-284.		0

#	ARTICLE	IF	CITATIONS
109	Paucisymptomatic COVID-19 in lung transplant recipient following two doses of mRNA-1273 (Moderna) vaccine. Journal of Heart and Lung Transplantation, 2021, 40, 1019.	0.6	0
110	Vaccination Strategies in Solid Organ and Stem Cell Transplant. , 2020, , 1-32.		0